AzTrials
AzTrials

ARDS, HumanNorthCARDSNCT04729075

Associations Between COVID-19 ARDS Treatment, Clinical Trajectories and Liberation From Mechanical Ventilator - an Analysis of the NorthCARDS Dataset

An observational study of ARDS, Human and Covid19, run by Northwell Health at 1 site in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The mortality rates associated with COVID-19 related ARDS (COVIDARDS) have varied from observational reports from around the world. This has ranged from 44% (28 day mortality) in the UK to 36% (28 day mortality from ICU admission) in Italian studies, to 32% (all-cause 28 day mortality) in Spain. Read more about this study

Who is it for?
Any age
Conditions the study is for
ARDS, Human, Covid19
What is being tested?
ARDS and COVID19 treatments
How many people
1,800 participants
Where
1 siteUnited States
Study dates
19 Jan 2021to 19 Jan 2021
How long will I take part?
6 Months
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages Any age
  • All sexes
  • No healthy volunteers
  • Child, Adult, Older adult

Study population: COVID-19 ARDS patients receiving mechanical ventilation

Who may be able to join

  • Inpatients at any of the hospitals within the Northwell Health system
  • COVID19 PCR positive
  • meeting ARDS criteria (defined as)
  • PaO2:FiO2 <300 for at least 2 consecutive values (including 2 S/F values)
  • bilateral infiltrates
  • mechanical ventilation (NIMV or IMV with PEEP 5)
  • Timeframe March 1, 2020 until December 30, 2020

Who cannot join

  • Patients admitted for surgical procedures
  • infiltrates described as being due to cardiogenic pulmonary edema without COVID-19 pneumonia
  • improvement of paO2:FiO2 to > 300 within 48 hours

Trial locations and contacts

1 site in 1 country.

United States1 site
  • Feinstein Institutes for Medical Research

    Manhasset, New York, 11030

Other trials in United States

About this study

Official title: Towards Precision Medicine for COVID-19 ARDS - An Analysis of the NorthCARDS (Northwell Health COVID-19 ARDS) Dataset to Identify Associations Between Patient-level Factors, Inpatient Treatment and Clinical Trajectories on Mechanical Ventilation Liberation and Survival

The mortality rates associated with COVID-19 related ARDS (COVIDARDS) have varied from observational reports from around the world. This has ranged from 44% (28 day mortality) in the UK to 36% (28 day mortality from ICU admission) in Italian studies, to 32% (all-cause 28 day mortality) in Spain. Predictive models have identified risk factors for COVID-19 hospitalized patients' mortality to include male sex, obesity, age, obesity, comorbidities including chronic lung disease and hypertension, as well as biomarkers including high levels of D-Dimer, LDH and CRP. In addition, practice patterns, such as drugs that were administered, timing of mechanical ventilation and adherence to established lung protective ventilation protocols are known to be variable across sites and have changed over time.

The investigators propose to analyze outcomes for patients with COVIDARDS within the NorthCARDS dataset (a dataset of over 1500 patients with COVID-19 related ARDS across the Northwell Health System in the NYC metropolitan region and Long Island, NY) to understand differences in hospital survival and in the time to liberation from mechanical ventilation, specifically looking at the associations between baseline patient factors, changes in biomarkers, respiratory function and hemodynamics over time, and treatments administered. The analyses will be based on three hypotheses:

Read more

H.1. Worsening trajectories of: oxygenation index (OI), respiratory system compliance (C), and inflammatory markers will be associated with lower hospital survival.

H.2. Higher duration of deep sedation and paralytics will be associated with greater time to liberation from mechanical ventilation. This risk will be increased in patients with worsening trajectories of OI, C, and inflammatory markers over time.

H.3. Type of mechanical ventilator, specifically the time on portable mechanical ventilator, is associated with hospital mortality and with inability to liberate from mechanical ventilator despite controlling for risk factors of changes in OI, C and Inflammatory markers over time, and the use of paralytics and deep sedation.

Read the detailed description

The investigators will leverage the NorthCARDS dataset for this analysis. This dataset includes over 1500 persons admitted to the Northwell Health System who had PCR positive COVID19 testing and were invasively mechanically ventilated for ARDS. Registry development was initiated in April 2020 and continues with prospective data collection for all mechanically ventilated COVID19 ARDS patients among the Northwell Health hospitals. Data structuring and engineering is informed by weekly multi-disciplinary review including frontline clinicians, data scientists, biostatisticians and data engineers within medical informatics. Random selection of patients for individual 'manual' chart review occurs for data assumptions and recording.

The two outcomes to be modeled using multivariable regression analyses will be:

  1. Index hospital survival and
  2. Time to liberation from mechanical ventilation.

Liberation from mechanical ventilation will be defined as non-palliative extubation and persistent extubation for greater than one week. Outcomes will be obtained from electronic health record queries. Patients in whom the investigators do not have outcomes data by November 30,2020 will be censored in analyses, and descriptive statistics will be summarized and presented separately.

The investigators will approach this analysis using both hypothesis-driven methods wherein known risk factors for poor outcomes will be included in the multivariable regression models (logistic regression for Model 1, and Cox Proportional Hazards for Model 2); and investigators will also perform data-driven variable selection for the models. A priori defined risk factors that will be included in the models will be: Age, Gender, BMI, functional status at baseline (nursing home versus community admission), Comorbidities (coronary artery disease, Chronic Kidney Disease, Neurologic disorders, COPD, Diabetes, Active cancer, Hypertension); Inpatient treatments (for continuous values will be (max, median, trajectory)) including PEEP levels, Driving Pressure, FiO2, hypoxemia (Pao2:Fio2), type of mechanical ventilator (portable versus not), COVID-targeted medications (e.g., azithromycin, hydroxychloroquine, corticosteroids); and end-organ damage in-hospital: liver dysfunction, Kidney dysfunction, coagulopathy, (captured via SOFA scores), cardiac dysfunction, and shock requiring vasopressor/inotrope. Calendar-time, hospital type (community versus tertiary hospital) and hospital capacity (measured as number of hospital beds filled and time from admission order in ER to being transferred to an inpatient bed) will also be included in the analyses to account for temporal and systemic influences of outcomes.

The final models will include variables selected through a backward selection process, together with variables ranked highly through data-driven methods including a logistic regression model regularized by Lasso penalty and Cox Proportional Hazards Model regularized by Lasso penalty. Model performance will be assessed for Model 1 (hospital survival) using the C-statistic.

Model performance for Model 2 (time to mechanical ventilator liberation) will be based on the C-statistic adapted for censored data.

Missing Data management: When the outcome data is missing for Model (1) (hospital survival), if there is less than 5% of outcomes missing, complete case analysis will be used; if there is more than 5% missing, sensitivity analysis will be performed by assuming all the missing outcomes to be either expired or alive to see if the results are similar to those using complete case analysis.

When the outcome data is missing for Model (2) (liberation from mechanical ventilation) the missing outcome will be considered as censored.

If overall < 5% of our cohort has missing data for any risk factors, only patients with complete values for all risk factors will be included (others will be discarded).

If > 5% of the cohort is missing data for any risk factor, the missing data will be imputed using multiple imputation.

If a risk factor is missing in > 50% of patients the variable will not be included in the analysis.

Feature Engineering/Data Reduction: We will also test whether combinations of covariables considered as one covariable increases model performance. This will include COVID-19 illness index (combination of hyperinflammatory markers, PaO2:FiO2 index at the time of intubation, requiring vasopressors at the time of intubation, and Oxygenation Index) and adherence to standard ARDS treatment protocols (Driving Pressure, whether receiving less than 6-8 cc/kg predicted body weight and whether or not proned).

Conditions
ARDS, Human, Covid19
Being tested
ARDS and COVID19 treatments
Medical subject headings
Respiratory Distress Syndrome, COVID-19

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • ARDS and COVID19 treatmentsOther

    Interventions that will be analyzed will include: immunomodulation; oxygen supplementation type, duration and level; mechanical ventilation type, duration; diuresis; inotrope/vasopressors; prone positioning

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Index Hospital Survival

    Through duration of hospital stay for up to 1 year

    Measured: up to 1 year

  2. Time to Mechanical Ventilator Liberation

    Censored at 6-months of follow-up; Liberation from mechanical ventilation will be defined as non-palliative extubation and persistent extubation for greater than one week.

    Measured: 6 months

Secondary outcomes (1)
  1. Hospital Readmission

    Within 6 months of follow up after index hospitalization

    Measured: 6 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted28 Jan 2021
  2. Study start19 Jan 2021
  3. Primary completion19 Jan 2021
  4. Study completion19 Jan 2021

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Other
Enrolment
1,800 participants (actual)
Target duration
6 Months
IDs, dates and publications
ClinicalTrials.gov ID
NCT04729075
Sponsor's protocol ID
19-0598
Acronym
NorthCARDS
Status last verified
Mar 2023
First submitted
19 Jan 2021
Last updated
4 Apr 2023
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Undecided: Access to the NorthCARDS Registry is planned via DUA

Publications

  • Cheyne H, Gandomi A, Hosseini Vajargah S, Catterson VM, Mackoy T, McCullagh L, Musso G, Hajizadeh N. Drivers of mortality in COVID ARDS depend on patient sub-type. Comput Biol Med. 2023 Nov;166:107483. doi: 10.1016/j.compbiomed.2023.107483. Epub 2023 Sep 16.

    PubMed 37748219

Questions about this trial

What is this clinical trial studying?

An observational study of ARDS, Human and Covid19, run by Northwell Health at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 7 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 4 Apr 2023. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Index Hospital Survival (time frame: up to 1 year). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT04729075, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 4 Apr 2023.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in